Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

Abstract. Background:. The isatuximab, pomalidomide, and dexamethasone (Isa-Pd) regimen has shown survival benefits for relapsed and/or refractory multiple myeloma (RRMM) in several trials, while evidence of effectiveness and safety among Chinese patients is limited. This study aimed to provide rea...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Wenting Chen, Jianhua You, Li’e Lin, Xiaojing Yan, Gang An, Yafei Wang, Weiwei Tian, Kaiyang Ding, Xi Zhang, Wenming Chen, Yingxue Wang, Baijun Fang, Jing Liu, Weilin Xia, Zhaoyi Feng, Lei Zhou, Zhini Wang, Dan Shen, Gang Liu, Weili Zhao, Sihan Zhou, Xiuyuan Hao
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wolters Kluwer 2026-02-01
سلاسل:	Chinese Medical Journal
الوصول للمادة أونلاين:	http://journals.lww.com/10.1097/CM9.0000000000003649
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!